[go: up one dir, main page]

WO2020161501A1 - Dosage d'inhibition transcriptionnelle - Google Patents

Dosage d'inhibition transcriptionnelle Download PDF

Info

Publication number
WO2020161501A1
WO2020161501A1 PCT/GB2020/050281 GB2020050281W WO2020161501A1 WO 2020161501 A1 WO2020161501 A1 WO 2020161501A1 GB 2020050281 W GB2020050281 W GB 2020050281W WO 2020161501 A1 WO2020161501 A1 WO 2020161501A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
transcription
assay
dna
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2020/050281
Other languages
English (en)
Inventor
Glenn Burley
Simon Paul Mackay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Strathclyde
Original Assignee
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Strathclyde filed Critical University of Strathclyde
Publication of WO2020161501A1 publication Critical patent/WO2020161501A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Definitions

  • the present invention relates to nucleic acid constructs for use in transcription assay and to transcription assays employing such constructs, which are designed to be used to facilitate the identification of compounds which modulate, such as inhibit, DNA transcription, by targeting a specific DNA sequence.
  • RNA polymerase which catalyses the synthesis of an RNA molecule with a nucleotide sequence complementary to its corresponding DNA template.
  • the initiation and elongation phases of transcription are highly regulated and involve an orchestrated series of protein-protein and protein-nucleic acid interactions in order to guide the RNAP to its promoter, to initiate the synthesis of a target RNA molecule.
  • the large number of proteins involved in transcription initiation, promoter release and active elongation provide multiple targets for inhibitory small molecules in anti-cancer and anti-microbial therapies (1-3).
  • transcription is fundamental to all living organisms, there is a dearth of methods available to assay direct transcriptional inhibition in real-time (2). Whilst gel electrophoresis-based footprinting, chromatin immunoprecipitation (DNA ChIP) and deep-sequencing provide valuable information concerning the potency and selectivity of transcriptional inhibition, they are typically low-throughput and labour-intensive. A more direct method to detect small molecule transcriptional inhibitors would be one which correlates the synthesis of a specific RNA molecule with a fluorescent read-out.
  • a recent application of a direct fluorescence-based reporter of transcription is the Spinach TART assay (4).
  • a fluorogenic Spinach aptamer sequence installed downstream to an RNA sequence of interest is used to directly correlate target RNA synthesis with an increase in fluorescence emission of the small molecule DFHBI when bound to the Spinach aptamer.
  • the Spinach-TART assay was used to evaluate the dose-dependence of T7 RNAP inhibition using heparin, wherein a loss of DFHBI fluorescence is directly proportional to the heparin concentration.
  • the present teaching is based on the development of a variant of the Spinach TART assay in order to identify compounds which modulate transcription through sequence selective DNA binding.
  • an assay construct for identifying a compound, which inhibits transcription through DNA binding comprising in sequence (5’-3’): an RNA promoter sequence, a compound DNA target sequence and a transcription reporter sequence.
  • a feature of the present invention is the ability to identify compounds which are capable of modulating, for example an inhibitory or activating effect, on DNA transcription by virtue of a compound binding to a specific DNA sequence, rather than effecting transcription by other means, such as binding to an RNA polymerase or non- specifically binding to DNA.
  • Non-specific binding to DNA may include DNA inter chelating compounds.
  • the user upon conducting assays using both types of constructs, the user will be able to ascertain whether or not a particular compound is modulating transcription by specifically binding to the DNA target sequence, or if transcription is being modulated by another mode of action, such as by way of acting directly upon the RNA polymerase, or by non-specific DNA binding.
  • the target DNA sequence may be a wild-type or mutant sequence and this may allow a user to identify compounds which differentially or preferentially bind to a wild-type or mutant, for example a single nucleotide polymorphism (SNP), sequence.
  • SNP single nucleotide polymorphism
  • the present inventors have shown that minor alterations in the target DNA sequence, such by only one or two nucleotide alterations, can lead to detectable and optionally quantifiable changes in the degree/level of transcription.
  • constructs and assays of the present invention can be used in order to observe the effects minor DNA sequence changes can have in terms of a compound’s ability to modulate transcription.
  • minor DNA sequence changes can have in terms of a compound’s ability to modulate transcription.
  • a compound has in terms of modulating transcription of wild-type and mutant target DNA sequences. This may be attractive, for example, in terms of identifying compounds, which are capable of activating or inhibiting transcription of wild-type or mutant sequences, or to identify compounds which are capable of selectively modulating transcription of only a wild-type or mutant sequence.
  • the evidence also supports the possibility that minor changes to a compound structure may lead to differences in a compounds ability to modulate transcription of a wild-type or mutant sequence.
  • a compound is known to modulate transcriptional activity of a wild-type sequence
  • rational design and alteration of the compound structure can be carried out in order to identify compounds which are capable of modulating transcription of a mutant sequence in a similar or alternative manner.
  • the compound may be obtained from a wide variety of sources including iibraries of synthetic or naturai compounds.
  • sources including iibraries of synthetic or naturai compounds.
  • numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides.
  • libraries of naturai compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.
  • natural and synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means.
  • known pharmacological agents may be subject to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc., to produce structural analogs.
  • Suitable compounds may encompass numerous chemical classes, though typically they are organic compounds; preferably small organic compounds. Small organic compounds generally have a molecular weight of more than 50 yet less than about 3,500, typically less than about 2000.
  • Candidate agents typically comprise functional chemical groups necessary for structural interactions with DNA, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two or more of said functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the aforementioned functional groups.
  • Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof, and the like.
  • One class of molecules which may be suitable for use in accordance with the present invention are pyrrole-imidazole polyamides (i5).
  • Compounds shown to modulate transcription through sequence selective binding may provide valuable reagents or precursors to the pharmaceutical and agricultural industries for cellular, plant, field crop, animal and/or human applications.
  • any suitable compounds which are identified to modulate transcription through sequence selective binding may find use in treating disease.
  • the RNA promoter sequence may be a eukaryotic or prokaryotic promoter sequence.
  • eukaryotic promoter or "prokaryotic promoter” as used herein refer to promoters recognized by the transcription machinery of a eukaryotic or a prokaryotic cell, respectively. Suitable prokaryotic promoter sequences may be recognizable by T7, T3, SPC or E.coli RIMA polymerases, for example. For eukaryotic RNA promoters, the sequence mat be recognizable by any of RNA polymerase I - V. However, in certain embodiments, the RNA promoter sequence is recognizable by R A polymerase li(6).
  • an assay may initially be conducted using a construct employing a prokaryotic promoter in order to identify a limited number of compounds and such limited number of compounds thereafter provided to a construct employing a eukaryotic promoter, such as an RNAP P promoter, as it may be more complex and/or expensive to conduct all tests using a eukaryotic system.
  • a prokaryotic promoter such as an RNAP P promoter
  • the transcription reporter sequence typically encodes a nucleic add aptamer that can bind selectively to conditionally fluorescent molecules (“fluorophores”) to enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength.
  • fluorophores conditionally fluorescent molecules
  • Aptamers are nucleic add molecules characterized by a single-strand and having a secondary structure that may possess one or more stems (i.e., base-paired regions) as well as one or more non base-paired regions along the length of the stem. These non- base-paired regions can be in the form of a bulge or loop (e.g., internal loop) along the length of the siem(s) and/or a loop at the end of the one or more stem(s) (e.g , hairpin loop).
  • stems i.e., base-paired regions
  • non base-paired regions can be in the form of a bulge or loop (e.g., internal loop) along the length of the siem(s) and/or a loop at the end of the one or more stem(s) (e.g , hairpin loop).
  • nucleic add aptamers possess specificity in binding to a particular target molecule, and they non-covantely bind their target molecule through an interaction such as an ion-ion force, dipole-dipole force, hydrogen bond, van der Waals force, electrostatic interaction, stacking interaction or any combination of these interactions.
  • RNA aptamers that bind to conditionally fluorescent molecules derived from the chromophore of green fluorescent protein.
  • Other suitable sequences include Genetically encoded "Spinach” RNA Is an aptamer capable of binding to, and turning on, a cell-permeable, non-toxic ligand, to emit GFP-iike fluorescence (7). More recently aptamers such as "Broccoli” RNA (8) and “Mango” RNA (Dolgosheina E.V. et al., ACS Chem. Biol., 2014, Vol. 9(10), pages 2412- 2420) were successfully used in live-cell imaging of small molecules and metabolites and may also be used. In one embodiment iSpinach RNA aptamer (Autour et al) may be used.
  • the fluorophores recognized by the nucleic acid aptamers of the present invention include those that possess a methyne (also known as methine) bridge between a substituted aromatic ring system and a substituted imidazol(thi)one, oxazol(thi)one. pyrrolin(thi)one, or furan(thi)one ring.
  • the methyne bridge contains a single carbon that is double-bonded to a ring carbon of the substituted imidazol(thi)one, oxazoi ⁇ thl)one, pyrrolin(thi)one, or furan(thi)one ring.
  • these conditionally fluorescent compounds are unlike cyanine dyes characterized by a poiymethyne bridge.
  • Exemplary fiuorophores identified in the above-referenced PCT Application Pubi. No. WO/2Q 10/096584 to Jaffrey and Paige include, without limitation, 4-(3,4.5 ⁇ trimethoxybenzylidene)-1 ,2-dimethy!-imidazol-5-one (“T BG); 4- ⁇ 4-hydroxy-3,5 ⁇ dimethoxybenzyjidene)-1 ,2-dimethyj-imidazoj-5-one (“DMHBi”).
  • the signal-emitting ligand is hydroxy benzyiideneimidazolinone (HBI), a derivative of HBI, thiazole orange (TO), or a derivative of TO.
  • the signal- emitting ligand is 3,5-difluoro-4-bydroxy benzyiideneimidazolinone (DFHBi), DFHBI-1T, DFHBI-2T or TOI-Blotin.
  • DFHBi 3,5-difluoro-4-bydroxy benzyiideneimidazolinone
  • DFHBI-1T 3,5-difluoro-4-bydroxy benzyiideneimidazolinone
  • DFHBI-2T 3,5-difluoro-4-bydroxy benzyiideneimidazolinone
  • the fiuorophores used in the present invention are characterized by a low quantum yield at a desired wavelength in the absence of aptamer binding in certain embodiments, the quantum yield of the fluorophore, in the absence of specific aptamer binding, is iess than about 0.01 , more preferably less than about 0.001 , most preferably less than about 0.0001.
  • the fiuorophores are substantially unable to exhibit increases in quantum yield upon binding or interaction with molecules other than the aptamer(s) that bind specifically to them. This includes other molecules in a cell or sample besides those aptamer molecules having a polynucleotide sequence that was selected for binding to the fluorophore.
  • the fiuorophores are preferably water soluble, non-toxic, and ceil permeable.
  • the fluorophore is soluble in an aqueous solution at a concentration of 0.1 pM, 1 mM, more preferably 10 pM, and most preferably 50 m or higher.
  • incubating a cell with these concentrations of the fluorophore does not affect the viability of the cell.
  • the fiuorophores are preferably capable of migrating through a cell membrane or cell wall into the cytoplasm or periplasm of a cell by either active or passive diffusion.
  • the fluorophore is able to migrate through both the outer and inner membranes of gram-negative bacteria, the cell wail and membrane of gram- positive bacteria, both the ceil wall and plasma membrane of plant cells, cell wall and membrane of fungi and molds (e.g yeast), the capsid of viruses, and/or the plasma membrane of an animal cell.
  • the fluorophore is able to migrate through both the outer and inner membranes of gram-negative bacteria, the cell wail and membrane of gram- positive bacteria, both the ceil wall and plasma membrane of plant cells, cell wall and membrane of fungi and molds (e.g yeast), the capsid of viruses, and/or the plasma membrane of an animal cell.
  • the terms“enhance the fluorescence signal” or“enhanced signal” refer to an increase in the quantum yield of the fluorophore when exposed to radiation of appropriate excitation wavelength, a shift in the emission maxima of the fluorescent signal (relative to the fluorophore emissions in ethanol glass or aqueous solution), an increase in the excitation coefficient, or two or more of these changes.
  • the increase in quantum yield is preferably at least about 1.5- foid, more preferably at least about 5 to 10-fold, at least about 20 to 50-foid, more preferably at least about 100 to about 200-fold. Fold increases in quantum yield exceeding 500-fold and even 1000-fold have been achieved with the present invention.
  • the radiation used to excite the fluorophore may be derived from any suitable source, preferably any source that emits radiation within the visible spectrum or Infrared spectrum.
  • the radiation may be directly from a source of radiation (e.g., a light source) or indirectly from another fluorophore (e.g., a FRET donor fluorophore).
  • a source of radiation e.g., a light source
  • another fluorophore e.g., a FRET donor fluorophore
  • Directly attaching the DNA target sequence to the sequence encoding the aptamer sequence may be less than desirable.
  • a sequence encoding a ribozyme sequence such as a hammerhead ribozyme sequence, is positioned between the DNA target sequence and the sequence encoding the aptamer sequence in this manner after transcription occurs, ribozyme cleavage of the DNA sequence selective binding sequence occurs, leaving the ribozyme sequence attached to the aptamer sequence.
  • Suitable ribozyme sequences are disclosed in (11) and (12), to which the skilled reader is directed.
  • a method for identifying a compound, which inhibits transcription through targeted DNA binding comprising: providing a compound to a transcription assay mixture comprising an assay construct in accordance with the present invention and described herein and detecting any signal generated by a reporter molecule binding to a transcribed reporter sequence.
  • the reporter molecule and reporter sequence may typically be the aptamer and fluorophore molecules as described above.
  • the transcription assay generally includes one or more additional reagents, such as salts, buffers, etc. to facilitate optimal protein-nucleic add binding.
  • additional reagents such as salts, buffers, etc. to facilitate optimal protein-nucleic add binding.
  • additional reagents such as salts, buffers, etc. to facilitate optimal protein-nucleic add binding.
  • additional reagents such as salts, buffers, etc. to facilitate optimal protein-nucleic add binding.
  • additional reagents such as salts, buffers, etc. to facilitate optimal protein-nucleic add binding.
  • reagents like detergents which may be used to reduce non-specific or background protein ⁇ substrate : nucleic acid-substrate, protein-protein and protein-DNA interactions, etc.
  • reagents that otherwise improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, antimicrobial agents, etc. may be used.
  • the assay method may be performed at any temperature which facilitates optimal binding, typically between 4° and 40° C., more commonly between 15° and 4G C C. Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening. Typically, the reagents are coincubated between 0.1 and 10 hours, preferably less than 5 hours, more preferably less than 2 hours each; of course, the incubations may and preferably do run simultaneously.
  • the assay methods of the present invention may be suited to automated high throughput compound screening.
  • the individual sample incubation volumes are less than about 500 ui, preferably less than about 250 ul, more preferably less than about 100 ul.
  • Such small sample volumes minimize the use of often scarce candidate compounds, and expensive transcription complex components.
  • the methods provide for automation, especially computerized automation. Accordingly, the method steps are preferably performed by a computer-controlled electromechanical robot.
  • the computer is loaded with software which provides the instructions which direct robotic operations and provides input (e.g. keyboard and/or mouse) and display (e.g. monitor) means for operator interfacing.
  • the assays are conducted in viino, and may be celi based or ceil free assays if ceil based, the assay is carried out in a suitable ceil and the relevant RNA polymerase may be provided by the cell. In cell free systems, it will be necessary to provide a source of the relevant RNA polymerase.
  • Figure 1 shows Representative plasmid maps of constructs used for STI assay a. DNA4.
  • Plasmids purchased from IDT Inc. and linearised via endonuclease cleavage prior to use in assay.
  • FIG. 2 shows - Overview of the Spinach Transcription Inhibition (STI) assay.
  • PT7 T7 RNAP promoter
  • SOI sequence of interest
  • HHR hammerhead ribozyme sequence
  • Reporter fluorogenic iSpinach aptamer (10);
  • Figure 4 shows Analysis of transcriptional inhibition using the STI assay a.
  • MOI Mechanism of Inhibition
  • Figure 5 shows Probing sequence-selective transcriptional inhibition of PIPs using the STI assay
  • a Structures of PA1 and PA2.
  • b SOI sequences used to explore PIP sequence selectivity
  • c Concentration-dependent decrease of iSpinach/DFHBMT fluorescence emission in the presence of PA1.
  • Data fit using a variable slope sigmoidal dose response curve (GraphPad Prism V.7) for n 3 ⁇ 1 s.d.
  • e Effect of SOI position on transcription inhibition.
  • Reagents and solvents were purchased from commercial sources and were used without further purification. Chlorambucil was purchased from Fluorochem. DFHBI-1T was purchased from Lucerna, Inc. T7 RNA polymerase (50,000 units/mL), ribonucleotide solution mix (25 mM), and EcoRV-HF ® (100,000 units/mL) were purchased from New England BioLabs. Ndel (10,000 units/mL) was purchased from Thermo-Fisher. All other reagents were purchased from Sigma-Aldrich. Incubation and shaking was performed on a Heidolph Instruments Titramax 1000 fitted with a Heidolph Incubator 1000. Fluorescence measurements were obtained in black 96 well 1 ⁇ 2-area microplates (Greiner Bio-One) using a Perkin Elmer Wallac Victor Multilabel plate reader fitted with 485/535 nm filters.
  • Plasmids containing designed DNA sequences were purchased from Integrated DNA Technologies, Inc. (Fig. 1). Plasmids were isolated on a large scale from 250 ml_ XL1- Blue cultures via alkaline lysis using laboratory-prepared buffers. Ethanol-precipitated plasmid DNA was linearised with either Ndel (DNA1 -4) or EcoRV-HF ® (DNA5-11). Linearised DNA was then purified by phenol:chloroform:isoamyl alcohol (25:24:1) extraction and ethanol precipitation and quantified by UV absorption at 260 nm.
  • Transcription assay buffer was prepared in RNAse-free water (6.7 mM 1 ,4- Dithiothreitol, 53 mM HEPES, 133 mM KCI, 13.3 mM MgCI2). The solution was heated in a water bath to 40 °C and buffered to pH 7.5 using 1 M NaOH.
  • the final volume for an individual well in a black 96 well 1 ⁇ 2-area microplate was 40 mI_. Final concentrations of components/well are given in the table below.
  • a 0.67 mM NTP-supplemented buffer solution was prepared by dissolving 25 mM NTPs (ATP, CTP, GTP, UTP) in assay buffer.
  • a 40 nM plasmid solution was prepared by dissolving the plasmid in NTP-supplemented buffer. 10 pL of the 40 nM plasmid solution was transferred to each well. The dilution series of the inhibitor was prepared in RNAse-free water and 10 pL of these dilutions were transferred to the appropriate wells in the 96-well plate. Finally, a solution of T7 RNAP (3.35 units/pL) and 2 mM DFHBI-1T in NTP-supplemented buffer was prepared and 20 L was transferred to each well.
  • Transcription assay buffers were prepared as described above with either 133 mM KCI or NaCI and varying [MgCh] (13.3, 23.3, 33.3 mM).
  • a 100 nM DNA4 solution was prepared in RNAse-free water and 10 pL were added to a 96-well plate in triplicate.
  • NTP-supplemented buffers were prepared as described and 10 pL was added to the wells.
  • the T7 RNAP/DFHBI-1T solution was prepared as described and 20 pL were added to the wells.
  • the plate was then covered as described and incubated at 40 °C with shaking. Measurements were then taken at 15, 30, 45, 60, 90, 120 minutes. Following each measurement, the plate was re-covered and returned to the incubator. This experiment was repeated three times.
  • a 1.1 mM stock solution of a-amanitin was prepared by dissolving a-amanitin in RNAse-free water. A dilution series of a-amanitin was then prepared in RNAse-free water to provide an experimental concentration range of 0.1-100 mM. 10 pl_ of each dilution was added to a 96-well plate in triplicate. A solution of T7 RNAP (6.7 units/pL) was prepared by dissolving T7 RNAP in assay buffer and 10 pL were added to the wells. The solutions were mixed by pipetting and the plate was covered and incubated at room temperature for 20 minutes.
  • a solution of 40 nM DNA4 and 2 mM DFHBI-1T was prepared in 1 mM NTP-supplemented buffer and 20 mI_ were added to the wells. The plate was then incubated and measured as described. This experiment was repeated three times.
  • a 10 mM stock solution of actinomycin D was prepared by dissolving actinomycin D in DMSO. A dilution series of actinomycin D was then prepared in RNAse-free water to provide an experimental concentration range of 0.03-100 mM. 10 mI_ of each dilution was added to a 96-well plate in triplicate. A 40 nM DNA4 solution was prepared in NTP-supplemented buffer as described and 10 pL were added to each well. The T7 RNAP/DFHBI-1T solution was prepared as described and 20 mI_ were added to the wells. The plate was then incubated and measured as described. This experiment was repeated three times.
  • a 100 mM stock solution of chlorambucil was prepared by dissolving chlorambucil in DMSO.
  • a dilution series of chlorambucil was then prepared in RNAse-free water to provide an experimental concentration range of 1-1000 mM.
  • a 40 nM DNA4 preincubation mixture was prepared by dissolving stock DNA4 and 10 mI_ of the chlorambucil dilutions in RNAse-free water to give a final volume of 50 pL/dilution.
  • the preincubation mixtures were then incubated at 37 °C with shaking at 350 rpm for 2.5 hours. Upon completion of preincubation, 10 pL of each dilution was added to a 96-well plate in triplicate.
  • a 4 mM stock solution of heparin was prepared by dissolving heparin sodium salt in RNAse-free water and filtering through a 0.2 pm filter. A dilution series of heparin was then prepared in RNAse-free water to provide an experimental concentration range of 0.001-100 pM. 10 pL of each dilution was added to a 96-well plate in triplicate. A 40 nM DNA4 solution was prepared in NTP-supplemented buffer as described and 10 pL were added to each well. The T7 RNAP/DFHBI-1T solution was prepared as described and 20 pL were added to the wells. The plate was then incubated and measured as described. This experiment was repeated four times.
  • a 100 mM stock solution of temozolomide was prepared by dissolving temozolomide in DMSO.
  • a dilution series of temozolomide was then prepared in RNAse-free water to provide an experimental concentration range of 2-40,000 pM.
  • a 40 nM DNA4 preincubation mixture was prepared by dissolving stock DNA4 and 10 pL of the temozolomide dilutions in RNAse-free water to give a final volume of 50 pL/dilution.
  • the preincubation mixtures were then incubated at 37 °C with shaking at 350 rpm for 2 hours. Upon completion of preincubation, 10 pL of each dilution was added to a 96-well plate in triplicate.
  • Dilution series of chlorambucil and temozolomide were prepared in RNAse-free water to provide experimental concentration ranges of 1-1000 pM (chlorambucil) and 2- 40,000 pM (temozolomide).
  • a 40 nM DNA4 mixture was prepared by dissolving stock DNA4 and 10 pL of the inhibitor dilutions in RNAse-free water to give a final volume of 50 pL/dilution. The preincubation mixtures were then incubated at 37 °C with shaking at 350 rpm for 2.5 h (chlorambucil) and 2 h (temozolomide).
  • Polyamide stock solutions (1 mM) were prepared from ditrifluoroacetate salts in RNAse-free water. Solutions were kept for four days and discarded to prevent aggregate formations from affecting results. Stocks were stored at -20 °C when not in use over the experimental period. During the experiment, stocks were warmed to 40 °C and periodically sonicated to minimise aggregate concentrations.
  • a dilution series of polyamide was prepared in RNAse-free water to provide experimental concentration ranges of 10-10,000 nM (PA1) and 10-1000 nM (PA2). 10 pl_ of each dilution was added to a 96-well plate. 40 nM solutions of DNA4-9 were prepared in NTP-supplemented buffer as described and 10 pL were added to each well. The T7 RNAP/DFHBI-1T solution was prepared as described and 20 pl_ were added to the wells. The plate was then incubated and measured as described. This experiment was repeated three times/polyamide/DNA construct.
  • % inhibition inhibition was calculated as % fluorescence compared to untreated sample. Inhibitor concentrations were converted to log[inhibitor] and data from 3-4 independent tests were fit using variable slope sigmoidal dose response curves. Standard deviations were calculated and plot within GraphPad. IC50 data for each independent curve (calculated in GraphPad) were averaged and used to calculate the reported SEM.
  • NMR spectroscopy was carried out using a Bruker AV 500 MHz spectrometer. All chemical shifts (d) were referenced to the deuterium lock and are reported in parts per million (ppm) and coupling constants are quoted in hertz (Hz). Abbreviations for splitting patterns are s (singlet), d (doublet), t (triplet) and m (multiplet). NMR data was processed using MestReNova. HRMS spectra were measured on a Bruker microTOFq High Resolution Mass Spectrometer.
  • Polyamides were purified by semi-preparative HPLC on a 150x21.2 mm Kinetex 5 pm C18 column using a Dionex Ultimate 3000 series HPLC equipped with a VWD-3400 variable wavelength detector. Purifications were performed using aqueous 0.1 % trifluoroacetic acid as Solvent A and acetonitrile/0.1% trifluoroacetic acid as Solvent B and were run at a flow rate of 9 mL/min using the following method: absorbance detector set at 310 nm. 10% B for 5 minutes, 10-60% B over 20 minutes, 60-90% B over 3 minutes, 90% B for 2 minutes, 90-10% B over 1 minute, 10% B for 10 minutes.
  • Pyrrole-imidazole (Py-lm) polyamides were prepared by manual solid phase synthesis as previously described ⁇ see (5)
  • the DNA construct used in our STI assay consists of four modules: (i) a T7 promoter, (ii) a DNA sequence of interest (SOI) to assess sequence-selectivity of DNA-binding, (Hi) a hammerhead ribozyme sequence (HHR) to cleave the fluorescence reporter and thus ensure that the fluorescence output can be benchmarked across constructs, and (iv) a Spinach reporter which is used to correlate RNA synthesis with a fluorescent output when bound to the small molecule fluorophore DFHBI-1T (Fig. 2).
  • SOI DNA sequence of interest
  • HHR hammerhead ribozyme sequence
  • RNAP inhibitors heparin and a-amanitin the DNA intercalator actinomycin D, the DNA cross-linker chlorambucil, and the clinically-approved methylating agent temozolomide (TMZ).
  • heparin and actinomycin D required no pre-incubation with their respective targets, a-amanitin was pre-incubated with T7 RNAP for 20 min and chlorambucil and TMZ were pre-incubated with DNA4 for 2.5 and 2 hours, respectively (Fig. 4b).
  • the most potent inhibitor in this suite of compounds was the RNAP inhibitor heparin (IC5 0 100 ⁇ 5 nM), whereas a-amanitin did not induce any transcriptional inhibition, which is in agreement with its specificity for RNAPII over T7 RNAP.
  • PIPs are programmable minor groove binders which bind to target DNA sequences 7-24 base-pairs in length with nanomolar binding affinity and have demonstrated efficacy as gene selective transcriptional modulators ((13-18)).
  • DNA constructs (DNA10-11) were prepared and compared with DNA5 (Fig. 5d).
  • DNA5 Fig. 5d
  • PA1 strongest inhibition of fluorescence was observed when the SOI was upstream of the HHR and iSpinach modules (DNA5, Fig. 5d).
  • the DNA8 construct contains the target binding sequence (5'- AAGGCAA), with the remaining constructs (DNA5-7.9) containing sequence mismatches in their SOI module (Fig. 5b).
  • the baseline IC50 value for PA2 was 596 ⁇ 25 nM (Fig. 5e).
  • PA2 exhibited potent transcriptional inhibition (IC50 103 ⁇ 4 nM) using DNA8, which contained its target sequence relative to mismatched constructs DNA5-7.9 (Fig. 5e).
  • STI assay identifies different types of transcriptional inhibitory mechanisms
  • the STI assay identified the strongest transcriptional inhibitors as heparin (IC50 100 ⁇ 5 nM) and actinomycin D (IC50 3.1 ⁇ 0.1 mM). These inhibitors have distinct mechanisms of action. Heparin inhibits transcriptional initiation of T7 RNAP by binding to the palm and finger subdomains, whereas actinomycin D indirectly inhibits transcriptional elongation by DNA intercalation i.e., indirect T7 RNAP inhibition by disrupting formation of the ternary transcriptional complex. Our method is also able to respond to differences in mechanistic specificity: a-amanitin is known to inhibit RNAPII but not T7 RNAP, which is reflected by the absence of an effect in our assay.
  • the DNA-damaging agents chlorambucil and TMZ exhibit far weaker levels of transcriptional inhibition. This observation is aligned with the primary mechanisms of cytotoxic action of both chlorambucil and TMZ being the inhibition of DNA replication and the DNA-damage repair pathway machinery respectively, which occur at much lower concentrations in cells than reported in our in vitro assay.
  • Sequence selective inhibition of transcriptional elongation by DNA binding polyamides generally correlates with the binding affinity for a target dsDNA sequence
  • the STI assay can be used to identify sequence-selective inhibitors of transcription.
  • This assay therefore has the potential to be automated into a high-throughput assay and could be used more generally as an initial screening platform to identify inhibitors of T7 RNAP or possibly RNAPII-mediated transcription.
  • Our results also show that the effect of PIP binding to DNA sequences on transcriptional elongation is quantifiable, which could act as a complementary tool to establish structure-activity profiles for this family of gene regulatory compounds.
  • RNA polymerase II senses obstruction in the DNA minor groove via a conserved sensor motif. Proc. Natl. Acad. Sci. USA, 113, 12426-12431.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des constructions d'acide nucléique destinées à être utilisées dans un dosage de transcription et des dosages de transcription utilisant de telles constructions, qui sont conçues pour être utilisées pour faciliter l'identification de composés qui modulent, notamment en l'inhibant, la transcription d'ADN, par ciblage d'une séquence d'ADN spécifique.
PCT/GB2020/050281 2019-02-07 2020-02-07 Dosage d'inhibition transcriptionnelle Ceased WO2020161501A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1901675.7 2019-02-07
GBGB1901675.7A GB201901675D0 (en) 2019-02-07 2019-02-07 Transcriptional inhibition assay

Publications (1)

Publication Number Publication Date
WO2020161501A1 true WO2020161501A1 (fr) 2020-08-13

Family

ID=65997051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2020/050281 Ceased WO2020161501A1 (fr) 2019-02-07 2020-02-07 Dosage d'inhibition transcriptionnelle

Country Status (2)

Country Link
GB (1) GB201901675D0 (fr)
WO (1) WO2020161501A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024082909A1 (fr) * 2022-10-18 2024-04-25 上海绅道生物科技有限公司 Procédé de détection pour le suivi en temps réel de la synthèse de l'arn par transcription in vitro

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096584A1 (fr) 2009-02-18 2010-08-26 Cornell University Système de reconnaissance/détection couplée pour une utilisation in vivo et in vitro

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096584A1 (fr) 2009-02-18 2010-08-26 Cornell University Système de reconnaissance/détection couplée pour une utilisation in vivo et in vitro

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
AUTOUR, A.WESTHOF, E.RYCKELYNCK, M.: "iSpinach: a fluorogenic RNA aptamer optimized for in vitro applications", NUCLEIC ACIDS RES., vol. 44, 2016, pages 2491 - 2500, XP055292326, DOI: 10.1093/nar/gkw083
BENSAUDE, O.: "Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?", TRANSCRIPTION, vol. 2, 2011, pages 103 - 108
BLACKLEDGE MEGHAN S ET AL: "Programmable DNA-binding small molecules", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, ELSEVIER, NL, vol. 21, no. 20, 18 April 2013 (2013-04-18), pages 6101 - 6114, XP028730976, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2013.04.023 *
BO LIU ET AL: "Simple reporter gene-based assays for hairpin poly(amide) conjugate permeability and DNA-binding activity in living cells", MOLECULAR BIOSYSTEMS, vol. 1, no. 4, 1 January 2005 (2005-01-01), GB, pages 307, XP055628974, ISSN: 1742-206X, DOI: 10.1039/b511514k *
CARLSON, C.D.WARREN, C.L.HAUSCHILD, K.E.OZERS, M.S.QADIR, N.BHIMSARIA, D.LEE, Y.CERRINA, F.ANSARI, A.Z.: "Specificity landscapes of DNA binding molecules elucidate biological function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, 2010, pages 4544 - 4549
DERVAN, P.B.EDELSON, B.S.: "Recognition of the DNA minor groove by pyrrole-imidazole polyamides", CURR. OPIN. STRUCT. BIOL., vol. 13, 2003, pages 284 - 299, XP002516157, DOI: 10.1016/S0959-440X(03)00081-2
DOHERTY, E.DOUDNA, J.A.: "Ribozyme Structures and Mechanisms", ANNUREV.BIOPHYS, vol. 30, 2011, pages 457 - 475
DOLGOSHEINA E.V. ET AL., ACS CHEM. BIOL., vol. 9, no. 10, 2014, pages 2412 - 2420
EGUCHI, A.WLEKLINSKI, M.J.SPURGAT, M.C.HEIDERSCHEIT, E.A.KROPORNICKA, A.S.VU, C.K.BHIMSARIA, D.SWANSON, S.A.STEWART, R.RAMANATHAN,: "Reprogramming cell fate with a genome-scale library of artificial transcription factors", PROC. NATL. ACAD. SCI. USA, vol. 113, 2016, pages E8257 - E8266, XP055616223, DOI: 10.1073/pnas.1611142114
ERWIN, G.S.GRIESHOP, M.P.BHIMSARIA, D.DO, T.J.RODRIGUEZ-MARTINEZ, J.A.MEHTA, C.KHANNA, K.SWANSON, S.A.STEWART, R.THOMSON, J.A. ET : "Synthetic genome readers target clustered binding sites across diverse chromatin states", PROC. NATL. ACAD. SCI. USA, vol. 113, 2016, pages E7418 - E7427, XP055479308, DOI: 10.1073/pnas.1604847113
FILONOV, G.S. ET AL., J. AM. CHEM. SOC, vol. 136, 2014, pages 16299 - 16308
GOTTESFELD, J.M.MELANDER, C.SUTO, R.K.RAVIOL, H.LUGER, K.DERVAN, P.B.: "Sequence-specific Recognition of DNA in the Nucleosome by Pyrrole-Imidazole Polyamides", J. MOL. BIOL., vol. 309, 2001, pages 615 - 629, XP004626890, DOI: 10.1006/jmbi.2001.4694
HAMMAN, C ET AL.: "The Ubiquitous hammerhead ribozyme", RNA JOURNAL, vol. 8, 2012, pages 871 - 885
HARGROVE, A.E.MARTINEZ, T.F.HARE, A.A.KURMIS, A.A.PHILLIPS, J.W.SUD, S.PIENTA, K.J.DERVAN, P.B.: "Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide", PLOS ONE, vol. 10, 2015, pages e014316
HOFER, K.LANGEJURGEN, L.V.JASCHKE, A.: "Universal Aptamer-Based Real-Time Monitoring of Enzymatic RNA Synthesis", J. AM. CHEM. SOC., vol. 135, 2013, pages 13692 - 13694, XP055629061, DOI: 10.1021/ja407142f
HSU, C.F.PHILLIPS, J.W.TRAUGER, J.W.FARKAS, M.E.BELITSKY, J.M.HECKEL, A.OLENYUK, B.Z.PUCKETT, J.W.WANG, C.C.C.DERVAN, P.B.: "Completion of a programmable DNA-binding small molecule library", TETRAHEDRON, vol. 63, 2007, pages 6146 - 6151, XP025318064, DOI: 10.1016/j.tet.2007.03.041
KATARZYNA, T.KRZYSZTOF, W.: "Inhibitors of Bacterial Transcription are Compounds for Potent Antimicrobial Drugs", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol. 14, 2013, pages 1275 - 1286
KATHARINA HÖFER ET AL: "Universal Aptamer-Based Real-Time Monitoring of Enzymatic RNA Synthesis", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 135, no. 37, 18 September 2013 (2013-09-18), US, pages 13692 - 13694, XP055629061, ISSN: 0002-7863, DOI: 10.1021/ja407142f *
KAWAMOTO, Y.SASAKI, A.CHANDRAN, A.HASHIYA, K.IDE, S.BANDO, T.MAESHIMA, K.SUGIYAMA, H.: "Targeting 24 bp within Telomere Repeat Sequences with Tandem Tetramer Pyrrole-Imidazole Polyamide Probes", J. AM. CHEM. SOC., vol. 138, 2016, pages 14100 - 14107
KURMIS, A.A.YANG, F.WELCH, T.R.NICKOLS, N.G.DERVAN, P.B.: "A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer", CANCER RES., vol. 77, 2017, pages 2207 - 2212
M. MUNDE ET AL: "Structure-dependent inhibition of the ETS-family transcription factor PU.1 by novel heterocyclic diamidines", NUCLEIC ACIDS RESEARCH, vol. 42, no. 2, 23 October 2013 (2013-10-23), pages 1379 - 1390, XP055335515, ISSN: 0305-1048, DOI: 10.1093/nar/gkt955 *
MA, C.YANG, X.LEWIS, P.J.: "Bacterial Transcription as a Target for Antibacterial Drug Development", MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, vol. 80, 2016, pages 139 - 160
MEIER, J.L.YU, A.S.KORF, I.SEGAL, D.J.DERVAN, P.B.: "Guiding the Design of Synthetic DNA-Binding Molecules with Massively Parallel Sequencing", J. AM. CHEM. SOC., vol. 134, 2012, pages 17814 - 17822, XP055375787, DOI: 10.1021/ja308888c
NAN CHER YEO ET AL: "An enhanced CRISPR repressor for targeted mammalian gene regulation", NATURE METHODS: SUPPLEMENTARY INFORMATION, vol. 15, no. 8, 16 July 2018 (2018-07-16), New York, pages 611 - 616, XP055628873, ISSN: 1548-7091, DOI: 10.1038/s41592-018-0048-5 *
NICKOLS, N.G.DERVAN, P.B.: "Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide", PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 10418 - 10423, XP055290218, DOI: 10.1073/pnas.0704217104
PADRONI, G.PARKINSON, J. A.FOX, K. R.BURLEY, G. A.: "Structural Basis of DNA Duplex Distortion Induced by Thiazole-Containing Hairpin Polyamides", NUCLEIC ACIDS RES., vol. 46, 2018, pages 42 - 53
PAIGE, J.S.WU, K.Y.JAFFREY, S.R.: "RNA Mimics of Green Fluorescent Protein", SCIENCE, vol. 333, 2011, pages 642 - 646, XP055044003, DOI: 10.1126/science.1207339
WITHERS, J.M.PADRONI, G.PAUFF, S.M.CLARK, A.W.MACKAY, S.P.BURLEY, G.A.: "Molecular Sciences and Chemical Engineering", 2016, ELSEVIER, article "Reference Module in Chemistry"
XU, L.WANG, W.GOTTE, D.YANG, F.HARE, A.A.WELCH, T.R.LI, B.C.SHIN, J.H.CHONG, J.STRATHERN, J.N. ET AL.: "RNA polymerase II senses obstruction in the DNA minor groove via a conserved sensor motif", PROC. NATL. ACAD. SCI. USA, vol. 113, 2016, pages 12426 - 12431
YEO NAN CHER ET AL: "An enhanced CRISPR repressor for targeted mammalian gene regulation", NATURE METHODS, NATURE PUB. GROUP, NEW YORK, vol. 15, no. 8, 16 July 2018 (2018-07-16), pages 611 - 616, XP036559397, ISSN: 1548-7091, [retrieved on 20180716], DOI: 10.1038/S41592-018-0048-5 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024082909A1 (fr) * 2022-10-18 2024-04-25 上海绅道生物科技有限公司 Procédé de détection pour le suivi en temps réel de la synthèse de l'arn par transcription in vitro

Also Published As

Publication number Publication date
GB201901675D0 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
Mei et al. TERRA G-quadruplex RNA interaction with TRF2 GAR domain is required for telomere integrity
Li et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors
Wigle et al. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen™-based assay for antagonists of methyl-lysine binding proteins
Chang et al. High-throughput screen for small molecules that modulate the ATPase activity of the molecular chaperone DnaK
Lee et al. Phosphoproteomic analysis reveals that PP4 dephosphorylates KAP-1 impacting the DNA damage response
Aghajan et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase
Eggert et al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets
Lee et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14
Morgan et al. Insights into the development of chemical probes for RNA
Maciąg et al. ppGpp inhibits the activity of Escherichia coli DnaG primase
Jiang et al. Amplified detection of DNA ligase and polynucleotide kinase/phosphatase on the basis of enrichment of catalytic G-quadruplex DNAzyme by rolling circle amplification
Cesa et al. Inhibitors of difficult protein–protein interactions identified by high-throughput screening of multiprotein complexes
Shell et al. Xeroderma pigmentosum complementation group C protein (XPC) serves as a general sensor of damaged DNA
Yang et al. Stress granule-defective mutants deregulate stress responsive transcripts
Sancineto et al. Computer‐Aided Design, Synthesis and Validation of 2‐Phenylquinazolinone Fragments as CDK9 Inhibitors with Anti‐HIV‐1 Tat‐Mediated Transcription Activity
Wang et al. C17orf53 is identified as a novel gene involved in inter-strand crosslink repair
Vilema-Enríquez et al. Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells
Xiao et al. High-Throughput-Methyl-Reading (HTMR) assay: a solution based on nucleotide methyl-binding proteins enables large-scale screening for DNA/RNA methyltransferases and demethylases
Senarisoy et al. Forster Resonance Energy Transfer Based Biosensor for Targeting the hNTH1–YB1 Interface as a Potential Anticancer Drug Target
Madiraju et al. TR-FRET-based high-throughput screening assay for identification of UBC13 inhibitors
Ornaghi et al. A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast
WO2020161501A1 (fr) Dosage d'inhibition transcriptionnelle
Gilroy et al. The impact of the C-Terminal domain on the interaction of human DNA topoisomerase II α and β with DNA
Sommer et al. Applying a high-throughput fluorescence polarization assay for the discovery of chemical probes blocking La: RNA interactions in vitro and in cells
CN106222251B (zh) 基于共区域化识别激活的级联信号放大策略检测转录因子的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20704074

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20704074

Country of ref document: EP

Kind code of ref document: A1